Niemann-Pick Disease Type C in Adulthood – A Psychiatric and Neurological Disorder
require the introduction of more human data on illness effects and progression to merge with the existing animal models. Expansion of non-invasive neuroimaging techniques will be needed to allow for the probing of brain changes in vivo.31,64
Currently, miglustat remains
the only disease-specific drug available for adults and children suffering from NPC. The high rate of schizophrenia-like psychosis in NPC also makes it an interesting disease model and illness phenocopy to study with the aim of further understanding the neuropathology of major mental disorders. n
Pentchev PG, et al., Niemann-Pick Disease Type C: A Cellular Cholesterol Lipidosis. In: Valle DL (ed.), The Metabolic and Molecular Bases of Inherited Disease, New York: McGraw-Hill, 1995;2625–39.
Wenger DA, et al., Nine cases of sphingomyelin lipidosis, a new variant in Spanish-American Children. Juvenile variant of Niemann-Pick Disease with foamy and sea-blue histiocytes, Am J Dis Child, 1977;131:955–61.
3. 4. 5. 6. 7. 8. 9.
Walterfang M, et al., Post-ictal psychosis in adolescent Niemann-Pick disease type C, J Inherit Metab Dis, 2010 (Epub ahead of print).
Vanier MT, Suzuki K, Recent advances in elucidating Niemann-Pick C disease, Brain Pathol, 1998;8:163–74.
Pinto R,, et al., Prevalence of lysosomal storage diseases in Portugal, Eur J Hum Genet, 2004;12:87–92.
Meikle PJ, et al., Prevalence of lysosomal storage disorders, JAMA, 1999;281:249–54.
Winsor EJ, Welch JP, Genetic and demographic aspects of Nova Scotia Niemann-Pick disease (type D), Am J Hum Genet, 1978;30:530–38.
Vanier MT, Millat G, Niemann-Pick disease type C, Clin Genet, 2003;64:269–81.
Sevin M, et al., The adult form of Niemann-Pick disease type C, Brain, 2007;130:120–33.
10. Vanier MT, et al., Type C Niemann-Pick disease: biochemical aspects and phenotypic heterogeneity, Dev Neurosci, 1991;13:307–14.
11. Pacheco CD, Lieberman AP, The pathogenesis of Niemann-Pick type C disease: a role for autophagy?, Expert Rev Mol Med, 2008;10:e26.
12. Walterfang M, et al., The neuropsychiatry of Niemann-Pick type C disease in adulthood, J Neuropsychiatry Clin Neurosci, 2006;18:158–70.
13. Carstea ED, et al., Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis, Science, 1997;277:228–31.
14. Naureckiene S, et al., Identification of HE1 as the second gene of Niemann-Pick C disease, Science, 2000;290:2298–2301.
15. Higgins ME, et al., Niemann-Pick C1 is a late endosome- resident protein that transiently associates with lysosomes and the trans-Golgi network, Mol Genet Metab, 1999;68:1–13.
16. Neufeld EB, et al., The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo, J Biol Chem, 1999;274:9627–35.
17. Zhang M, et al., Sterol-modulated glycolipid sorting occurs in niemann-pick C1 late endosomes, J Biol Chem, 2001;276:3417–25.
18. Watari H, et al., Mutations in the leucine zipper motif and sterol-sensing domain inactivate the Niemann-Pick C1 glycoprotein, J Biol Chem, 1999;274:21861–6.
19. Liscum L, et al. The intracellular transport of low density lipoprotein-derived cholesterol is defective in Niemann- Pick type C fibroblasts, J Cell Biol, 1989;108:1625–36.
20. Sokol J, et al., Type C Niemann-Pick disease. Lysosomal accumulation and defective intracellular mobilization of low density lipoprotein cholesterol, J Biol Chem, 1988;263:3411–17.
21. Lloyd-Evans E, et al., Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium, Nat Med, 2008;14:1247–55.
22. Mutka AL, et al., Secretion of sterols and the NPC2 protein from primary astrocytes, J Biol Chem, 2004;279:48654–62.
23. Friedland N, et al., Structure of a cholesterol-binding EUROPEAN NEUROLOGICAL REVIEW
protein deficient in Niemann-Pick type C2 disease, Proc Natl Acad Sci U S A, 2003;100:2512–17.
24. Ko DC, et al., The integrity of a cholesterol-binding pocket in Niemann-Pick C2 protein is necessary to control lysosome cholesterol levels, Proc Natl Acad Sci U S A, 2003;100:2518–25.
25. Sleat DE, et al., Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport, Proc Natl Acad Sci U S A, 2004;101:5886–91.
26. German DC, et al., Neurodegeneration in the Niemann- Pick C mouse: glial involvement, Neuroscience, 2002;109:437–50.
27. Patel SC, et al., Localization of Niemann-Pick C1 protein in astrocytes: implications for neuronal degeneration in Niemann- Pick type C disease, Proc Natl Acad Sci U S A, 1999;96:1657–62.
28. Ory DS, Niemann-Pick type C: a disorder of cellular cholesterol trafficking, Biochim Biophys Acta, 2000;1529:331–9.
29. Patterson MC, et al., Niemann-Pick Disease Type C: A Lipid Trafficking Disorder. In: Scriver CR, Beaudet AL, Sly WS, Valle DL (eds), The Metabolic and Molecular Bases of Inherited Disease, New York: McGraw-Hill, 2001;3611–33.
30. Millat G, et al., Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop, Am J Hum Genet, 2001;68: 1373–85.
31. Walterfang M, et al., White and grey matter alterations in Niemann-Pick disease type C adults: a cross-sectional study, Neurology, 2010 (Epub ahead of print).
32. Ong WY, et al., Neurodegeneration in Niemann-Pick type C disease mice, Exp Brain Res, 2001;141:218–31.
33. Solomon D, et al., Niemann-Pick type C disease in two affected sisters: ocular motor recordings and brain-stem neuropathology, Ann N Y Acad Sci, 2005;1039:436–45.
34. German DC, et al., Selective neurodegeneration, without neurofibrillary tangles, in a mouse model of Niemann-Pick C disease, J Comp Neurol, 2001;433:415–25.
35. Walkley SU, Suzuki K, Consequences of NPC1 and NPC2 loss of function in mammalian neurons, Biochim Biophys Acta, 2004;1685:48–62.
36. Suzuki K, et al., Niemann-Pick disease type C: neuropathology revisited, Dev Brain Dysfunct, 1997;10:306–20.
37. Suzuki K, et al., Neurofibrillary tangles in Niemann-Pick disease type C, Acta Neuropathol, 1995;89:227–38.
38. Love S, et al., Neurofibrillary tangles in Niemann-Pick disease type C, Brain, 1995;118(Pt 1):119–29.
39. Kelly DA, et al., Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease, J Pediatr, 1993;123: 242–7.
40. Imrie J, Wraith JE, Isolated splenomegaly as the presenting feature of Niemann-Pick disease type C, Arch Dis Child, 2001;84:427–9.
41. Garver WS, et al., The National Niemann-Pick C1 disease database: report of clinical features and health problems, Am J Med Genet A, 2007;143A:1204–11.
42. Vanier MT, et al., Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients, Clin Genet, 1988;33:331–48.
43. Pineda M, et al., Miglustat in patients with Niemann-Pick Type C disease (NPC): a multicentre retrospective survey, J Inherit Metab Dis, 2008;31 (Suppl. 1):98.
44. Walterfang M, et al., Gender dimorphism in siblings with schizophrenia-like psychosis due to Niemann-Pick disease type C, J Inherit Metab Dis, 2009 (Epub ahead of print).
Mark Walterfang is a Consultant Neuropsychiatrist at the Neuropsychiatry Unit of the Royal Melbourne Hospital and the Melbourne Neuropsychiatry Centre at the University of Melbourne. He completed specialist training in psychiatry in 2000 and since this time has developed an interest in the neuropsychiatry of Niemann-Pick disease type C (NPC), which frequently presents with major mental illness.
45. Imrie J, et al., The natural history of Niemann-Pick disease type C in the UK, J Inherit Metab Dis, 2007;30:51–9.
46. Wraith JE, et al., Recommendations on the diagnosis and management of Niemann-Pick disease type C, Mol Genet Metab, 2009;98:152–65.
47. Argoff CE, et al., Type C Niemann-Pick disease: cellular uncoupling of cholesterol homeostasis is linked to the severity of disruption in the intracellular transport of exogenously derived cholesterol, Biochim Biophys Acta, 1991;1096:319–27.
48. Vanier MT, et al., Type C Niemann-Pick disease: spectrum of phenotypic variation in disruption of intracellular LDL- derived cholesterol processing, Biochim Biophys Acta, 1991;1096:328–37.
49. Wraith JE, et al., Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study, Mol Genet Metab, 2009;98:250–54.
50. Kandt RS, et al., Cataplexy in variant forms of Niemann- Pick disease, Ann Neurol, 1982;12:284–8.
51. Philippart M, et al., Gelastic cataplexy in Niemann-Pick disease group C and related variants without generalized sphingomyelinase deficiency, Ann Neurol, 1983;14:492–3.
52. Patterson MC, et al., The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann- Pick disease type C, Neurology, 1993;43:61–4.
53. Sylvain M, et al., Magnetic resonance spectroscopy in Niemann-Pick disease type C: correlation with diagnosis and clinical response to cholestyramine and lovastatin, Pediatr Neurol, 1994;10:228–32.
54. European Medicines Agency, European Public Assessment Report (EPAR) Zavesca, EPAR summary for the public, 2009. Available at: www.ema.europa.eu/
humandocs/PDFs/EPAR/zavesca/H-435-en1.pdf (accessed April 2010).
55. Treiber A, et al., The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat, Xenobiotica, 2007;37:298–314.
56. Platt FM, et al., N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis, J Biol Chem, 1994;269:8362–5.
57. Butters TD, et al., Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders, Chem Rev, 2000;100:4683–96.
58. Zervas M, et al., Critical role for glycosphingolipids in Niemann-Pick disease type C, Curr Biol, 2001;11:1283–7.
59. Patterson MC, et al., Miglustat for treatment of Niemann- Pick C disease: a randomised controlled study, Lancet Neurol, 2007;6:765–72.
60. Wraith JE, et al., Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial, Mol Genet Metab, 2010;99:351–7.
61. Kim SJ, et al., Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann-Pick type C disease improved by valproic acid, a histone deacetylase inhibitor, Biochem Biophys Res Commun, 2007;360:593–9.
62. Alvarez AR, et al., Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease, FASEB J, 2008;22:3617–27.
63. Liu B, et al., Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse, Proc Natl Acad Sci U S A, 2009;106:2377–82.
64. Galanaud D, et al., 24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy, Mol Genet Metab, 2009;96:55–8.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84
| Page 85
| Page 86
| Page 87
| Page 88
| Page 89
| Page 90
| Page 91
| Page 92
| Page 93
| Page 94
| Page 95
| Page 96
| Page 97
| Page 98
| Page 99
| Page 100
| Page 101
| Page 102
| Page 103
| Page 104
| Page 105
| Page 106
| Page 107
| Page 108
| Page 109
| Page 110
| Page 111
| Page 112
| Page 113
| Page 114
| Page 115
| Page 116